PHOENIX, AZ
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, founded in 2002, is a mid-sized nonprofit in the Medical Research sector that reported $85.9M in total revenue in fiscal year 2023. Revenue surged 73% from the prior year, signaling strong growth momentum.
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON DEVELOPING EARLIER AND SMARTER TREATMENTS BY EMPLOYING INNOVATIVE ADVANCES ARISING FROM THE HUMAN GENOME PROJECT AND APPLYING THEM TO THE DEVELOPMENT OF DIAGNOSTICS, PROGNOSTICS AND THERAPIES FOR CANCER, NEUROLOGICAL DISORDERS, DIABETES AND OTHER COMPLEX DISEASES.
NEUROGENOMICS THE NEUROGENOMICS DIVISION RESEARCH PROGRAMS SPAN ALL AGES, FROM DEVELOPMENTAL DISORDERS EARLY IN LIFE, THROUGH DISEASES OF ADULTHOOD SUCH AS NEURONAL DEGENERATION INCLUDING ALS...
NEUROGENOMICS THE NEUROGENOMICS DIVISION RESEARCH PROGRAMS SPAN ALL AGES, FROM DEVELOPMENTAL DISORDERS EARLY IN LIFE, THROUGH DISEASES OF ADULTHOOD SUCH AS NEURONAL DEGENERATION INCLUDING ALS, ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE AS WELL AS STROKE AND NEUROTRAUMA SUCH AS FROM CONCUSSION. OUR FIRST GOAL IS TO IMPROVE THE ABILITY TO DIAGNOSE NEUROLOGICAL DISEASE BEFORE IT STRIKES BY UNDERSTANDING THE INDIVIDUAL GENETIC AND EPIGENETIC VARIATION BETWEEN INDIVIDUALS. BECAUSE THESE DISEASES IMPACT SO MANY LIVES AROUND THE WORLD EITHER DIRECTLY (BY HAVING A DISEASE), OR INDIRECTLY (BY CARING FOR A LOVED ONE WITH THE DISEASE), THE SECOND GOAL CENTERS ON THE DEVELOPMENT OF NEW DRUG THERAPIES THAT SPECIFICALLY UTILIZE AN INDIVIDUAL'S GENETIC BACKGROUND. OVER THE PAST 20 YEARS, OUR INVESTIGATORS HAVE BEEN AWARDED DOZENS OF LARGE FEDERAL AND FOUNDATION GRANTS, AND DEVELOPED A RESEARCH CLINIC FOCUSED ON DIRECTLY INTERACTING WITH THE COMMUNITY AND PATIENTS IN THE AREA OF PRECISION MEDICINE.
CITY OF HOPE HAS A NON QUALIFIED SECTION 457(F) EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH...
CITY OF HOPE HAS A NON QUALIFIED SECTION 457(F) EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH DEFERRED COMPENSATION. THE PLAN VESTS AFTER THREE (3) FISCAL YEARS OF SERVICE AND THE VESTED TOTALS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN (B) (III). PRIOR TO VESTING, THE ANNUAL CONTRIBUTION AMOUNTS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN (C). PURSUANT TO THE PLAN DOCUMENT, VESTED PARTICIPANTS ARE ENTITLED TO WITHDRAW FROM THEIR VESTED ACCOUNT AN AMOUNT EQUAL TO THE FEDERAL, STATE, LOCAL AND FICA TAXES THEY OWE. THESE AMOUNTS ARE REMITTED TO THE APPROPRIATE TAXING AUTHORITIES ON BEHALF OF THE PARTICIPANTS. FOR CALENDAR YEAR 2023, THE FOLLOWING INDIVIDUALS WITHDREW THE REFERENCED AMOUNTS TO COVER SUCH TAXES: ROBERT STONE - $59,965 JEFFREY TRENT - $16,028
PATHOGEN AND MICROBIOME THE PATHOGEN AND MICROBIOME DIVISION IS FOCUSED ON DEVELOPING AND TRANSLATING MICROBIAL GENOMIC DISCOVERIES INTO APPLICATION TO ADVANCE HUMAN HEALTH IN THE AREAS OF CLINICAL...
PATHOGEN AND MICROBIOME THE PATHOGEN AND MICROBIOME DIVISION IS FOCUSED ON DEVELOPING AND TRANSLATING MICROBIAL GENOMIC DISCOVERIES INTO APPLICATION TO ADVANCE HUMAN HEALTH IN THE AREAS OF CLINICAL MEDICINE, PUBLIC HEALTH AND BIODEFENSE. THE DIVISION SEEKS TO ADVANCE OUR UNDERSTANDING OF MULTI-DRUG RESISTANT INFECTIONS, DEVELOP NOVEL GENOTYPING TECHNIQUES FOR GENOMIC EPIDEMIOLOGY AND MICROBIAL FORENSICS, FUNGAL EPIDEMIOLOGY AND PHYLOGENETICS, UNDERSTAND THE RELATIONSHIP OF MICROBES TO HUMAN HEALTH AND DISEASE, AND THROUGH THE TGEN NORTH CLIA LAB OFFER PCR AND SEROLOGY TESTING FOR SARS-COV-2. A MAJOR EMPHASIS IS ON ADAPTING AND ADVANCING NEXT-GENERATION SEQUENCING TOOLS FOR INFECTIOUS DISEASE RESEARCH AND HEALTHCARE SUCH AS DIAGNOSTIC TESTS TO CHARACTERIZE AND TRACK HOSPITAL ACQUIRED INFECTIONS, WITH AN EMPHASIS ON ANTIBIOTIC RESISTANCE, ALLOWING PHYSICIANS TO PROVIDE PERSONALIZED THERAPY AND CONTAIN OUTBREAKS. ASSAYS HAVE BEEN TAILORED TO MANY DISEASES, ORGANISMS AND SAMPLE TYPES, INCLUDING MRSA, TUBERCULOSIS, KLEB, E COLI AND STAPHYLOCOCCUS. THE DIVISION WORKS CLOSELY WITH ITS SISTER INSTITUTE AT NORTHERN ARIZONA UNIVERSITY, THE PATHOGEN AND MICROBIOME INSTITUTE, AS WELL AS WITH A NUMBER OF OTHER COLLABORATORS LOCALLY, NATIONALLY AND GLOBALLY. THE DIVISION HAS BEEN INSTRUMENTAL IN SOLVING NUMEROUS DISEASE OUTBREAKS AROUND THE WORLD, HAS GENERATED MULTIPLE INVENTIONS AND HAS LICENSED OUT INTELLECTUAL PROPERTY TO GOVERNMENTS AND BIOTECH COMPANIES.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $85,916,307 | $49,618,841 | +0.7% |
| Expenses | $84,441,597 | $81,144,473 | +0.0% |
| Net Income | $1,474,710 | $-31,525,632 | -1.0% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| JEFFREY M TRENT PHD | BOARD MEMBER/PRES/SCIENCE DIR. | 39.0 |
Officer
Director
|
$0 | $343,288 | $1,876,254 |
| ROBERT W STONE | BD & VICE CHRM/COH CEO & PRES. | 1.0 |
Officer
Director
|
$0 | $1,667,331 | $6,149,980 |
| WILLIAM J POST | BOARD MEMBER/CHAIRMAN | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| ANTHONY SCOTT | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| BENNETT DORRANCE | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| DAVID J GULLEN MD | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| KAREN QUINTOS | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| MARILYN QUAYLE | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| PAMELA KEHALY | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| RICHARD SILVERMAN | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| SHARON HARPER | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| TERRY PEETS | BOARD MEMBER | 1.0 |
Director
|
$0 | $0 | $0 |
| CRISTIN O'CALLAHAN | SECRETARY/COH GENERAL COUNSEL | 1.0 |
Officer
|
$0 | $341,123 | $1,472,461 |
| JENNIFER A PARKHURST | TREASURER/COH CFO (PT YR) | 1.0 |
Officer
|
$0 | $64,844 | $1,629,130 |
| KEVIN CAMPBELL | CHIEF INFORMATION OFFICER | 40.0 |
Officer
|
$275,299 | $25,617 | $300,916 |
| MANUEL ESTRADA | CFO/ASSISTANT TREASURER | 39.0 |
Officer
|
$439,142 | $36,511 | $475,653 |
| STEPHANIE MCRAE | GENERAL COUNSEL/ASST SECRETARY | 40.0 |
Officer
|
$383,664 | $24,503 | $408,167 |
| TERESA BURLESON | CHIEF OPERATING OFFICER | 39.0 |
Officer
|
$718,000 | $31,378 | $749,378 |
| DANIEL VON HOFF | PHYSICIAN IN CHIEF | 40.0 |
Key Emp
|
$825,361 | $23,105 | $848,466 |
| KENDALL JENSEN | DEPUTY DIR. OF RESEARCH RES. | 40.0 |
Key Emp
|
$408,623 | $34,724 | $443,347 |
| MICHAEL BERENS | DEPUTY DIRECTOR OF RESEARCH | 40.0 |
Key Emp
|
$468,875 | $31,435 | $500,310 |
| SUNIL SHARMA | DEPUTY DIR OF CLINIC. SCIENCES | 40.0 |
Key Emp
|
$612,970 | $29,636 | $642,606 |
| CHERYL BABO | GENERAL COUNSEL, ASSOCIATE | 40.0 |
Highest
|
$360,307 | $15,317 | $375,624 |
| CRISTIAN TOMASETTI | PROFESSOR | 40.0 |
Highest
|
$632,656 | $108,211 | $740,867 |
| GALEN PERRY | SR. VP OF MKTG & COMMUNICATION | 40.0 |
Highest
|
$392,474 | $33,590 | $426,064 |
| MATT HUENTELMAN | PROFESSOR | 40.0 |
Highest
|
$437,867 | $63,095 | $500,962 |
| NICHOLAS SCHORK | PROFESSOR | 40.0 |
Highest
|
$460,472 | $21,344 | $481,816 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $85,916,307 | $84,441,597 | $148,610,558 | $1,474,710 |
| 2023 | $49,618,841 | $81,144,473 | $145,155,331 | $-31,525,632 |
| 2022 | $47,789,496 | $74,504,945 | $174,203,210 | $-26,715,449 |
| 2021 | $175,687,790 | $99,192,595 | $224,233,974 | $76,495,195 |
| 2020 | $74,149,393 | $78,803,060 | $140,363,431 | $-4,653,667 |
| 2019 | $77,428,548 | $64,872,822 | $140,891,715 | $12,555,726 |
| 2018 | $57,643,920 | $57,255,533 | $136,019,915 | $388,387 |
Compare THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE with other nonprofits in Arizona and across the country.